Share This:
Search Results
The DNTP Technical Report (TR) Level of Evidence Criteria are available here: https://ntp.niehs.nih.gov/go/baresults. In the table below this information is further delineated into three fields:
- Level of Evidence: The overall category of evidence of carcinogenic activity for the TR, Species, Strain and Sex
- Organ Site Call: The level of evidence supported by the specific organ site for the TR, Species, Strain and Sex. When the Organ Site Call directly supports the TR Level Of Evidence the Finding Type flag is set to “Neoplastic Lesion”. Some Organ Site Calls could support a separate call of Equivocal Evidence; this is noted in Finding Type by the flag “May Have Been Related”
- Finding Type: Further identification of the Organ Site Call. Where this says “Neoplastic Lesion” the Organ Site Call supports the TR Level of Evidence and the Organ Site Call is the same as that of the TR. Where Finding Type says “May Have Been Related” the TR Level of Evidence for other responses led to an overall call of Clear or Some Evidence but the specified organ supports a call of Equivocal Evidence.
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| Yes | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| Yes | TR-127 | 99-59-2 | 5-Nitro-o-anisidine | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| Yes | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50 | Neoplastic Lesions |
| Yes | TR-368 | 389-08-2 | Nalidixic acid | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 4/46 10/46 11/47, PAPILLOMA 0/46 1/46 0/47, OR CARCINOMA 1/46 4/46 5/47 COMBINED 5/46 15/46 16/47 | Neoplastic Lesions |
| Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 7/48 10/32 10/62 10/50, CARCINOMA 4/48 9/32 19/62 15/50, COMBINED 11/48 17/32 28/62 23/50 | Neoplastic Lesions |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59 | Neoplastic Lesions |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50 | Neoplastic Lesions |
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51 | Neoplastic Lesions |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55 | Neoplastic Lesions |
| Yes | TR-498 | 99-99-0 | p-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Some Evidence | Some Evidence | ADENOMA OR CARCINOMA 8/50 12/50 20/50 8/49 | Neoplastic Lesions |
| Yes | TR-442 | 62-23-7 | p-Nitrobenzoic acid | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Some Evidence | Some Evidence | ADENOMA 4/50 12/49 10/49 12/50 OR CARCINOMA 1/50 2/49 5/49 4/50 COMBINED 4/50 14/49 15/49 15/50 | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 1/4 6/48 12/47 3/48 8/47 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 4/48 6/48 7/48 11/48 14/47 | Neoplastic Lesions |
| Exact Match | Publication No. | CASRN | Test Article Name | Species | Strain | Sex | Route | Organ | Level of Evidence | Organ Site Call | Tumor Type/Incidence | Finding Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Yes | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 2/50 6/50 7/51 10/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 1/52 2/51 10/54 11/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/49 0/47 1/52 2/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Intestines (Large) | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 0/50 2/48 1/52 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 20/49 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/50 6/49 12/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Male | Gavage | Oral Cavity | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56 | May Have Been Related |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Pancreas Acinar Cell | Clear Evidence | Clear Evidence | ADENOMA 5/50 21/50 36/49 29/52 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Female | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 1/59 0/60 4/60 | Neoplastic Lesions |
| No | TR-384 | 96-18-4 | 1,2,3-Trichloropropane | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 0/60 0/60 0/59 3/60 | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Rats | F344/N | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Mice | B6C3F1 | Female | Dosed-Feed | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Mice | B6C3F1 | Female | Dosed-Feed | Thyroid Gland C-Cell | Positive | Positive | ADENOMA OR CARCINOMA, ADENOMA | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Mice | B6C3F1 | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA | Neoplastic Lesions |
| No | TR-143 | 2243-62-1 | 1,5-Naphthalenediamine | Rats | F344/N | Female | Dosed-Feed | Uterus/Cervix | Positive | Positive | (POLYP) | Neoplastic Lesions |
| Yes | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Esophagus | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50 | May Have Been Related |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/50 5/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 44/50 49/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Nasal Cavity | Clear Evidence | Clear Evidence | ADENOMA 0/50 48/50 48/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Mice | B6C3F1 | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Vascular System (Spleen) | Clear Evidence | Clear Evidence | HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Female | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50 | Neoplastic Lesions |
| No | TR-400 | 96-13-9 | 2,3-Dibromo-1-propanol | Rats | F344/N | Male | Topical Application | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50 | Neoplastic Lesions |
| Yes | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Preputial Gland | Positive | Positive | (ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (SQUAMOUS CELL CARCINOMA OR BASAL CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland C-Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Mice | B6C3F1 | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Mice | B6C3F1 | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Female | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Thyroid Gland Follicular Cell | Positive | Positive | ADENOMA OR CARCINOMA | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | (SEBACEOUS ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-084 | 39156-41-7 | 2,4-Diaminoanisole sulfate | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (SQUAMOUS CELL CARCINOMA OR SEBACEOUS ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 2/44 3/75 1/60 | May Have Been Related |
| Yes | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/58 15/44 13/74 16/55; CARCINOMA 2/58 17/44 41/74 30/55 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 1/75 2/60 OR ADENOCARCINOMA 0/60 1/45 0/75 1/60 COMBINED 0/60 1/45 1/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 1/45 4/75 5/60 OR ADENOCARCINOMA 0/60 4/45 11/75 8/60 COMBINED 0/60 4/45 14/75 13/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 1/44 0/75 2/60 OR CARCINOMA 0/60 0/44 0/75 1/60 COMBINED 0/60 1/44 0/75 3/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 3/45 7/74 6/60; NEOPLASTIC NODULE OR CARCINOMA 1/60 1/45 0/74 2/60 COMBINED 1/60 4/45 7/74 8/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 1/60 2/45 14/75 20/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 2/60 1/45 7/75 6/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/60 2/45 3/75 3/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 3/75 2/60 COMBINED 2/60 2/45 6/75 5/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/60 7/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/60 1/45 0/75 2/60 COMBINED 1/60 8/45 10/75 11/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 14/60 6/43 19/73 12/59 OR CARCINOMA 2/60 6/43 15/73 19/59 COMBINED 16/60 12/43 33/73 29/59 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 0/60; BASAL CELL NEOPLASMS 0/60 4/45 3/75 2/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL OR SEBACEOUS GLAND NEOPLASMS 2/60 33/45 56/75 41/60; SQUAMOUS CELL NEOPLASMS 0/60 13/45 28/75 22/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 1/75 2/59 OR CARCINOMA 0/60 1/45 1/75 0/59 COMBINED 0/60 4/45 2/75 2/59 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 3/45 4/75 3/60 OR CARCINOMA 1/60 10/45 17/75 13/60 COMBINED 1/60 12/45 21/75 16/60 | Neoplastic Lesions |
| No | TR-372 | 20325-40-0 | 3,3'-Dimethoxybenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/59 4/45 11/75 9/60; CARCINOMA 0/59 7/45 14/75 21/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/60 1/45 1/75 0/60; GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 1/45 0/75 0/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | GLIOMA 0/60 0/45 1/75 1/60; MENINGIOMA 0/60 0/45 0/75 1/60; MENINGEAL SARCOMA 0/60 0/45 1/75 0/60 | May Have Been Related |
| Yes | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 9/45 32/75 17/59 OR CARCINOMA 0/60 5/45 11/75 18/59 COMBINED 0/60 14/45 42/75 32/59 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 1/60 3/45 6/75 4/60 | May Have Been Related |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 2/45 7/75 4/60 OR ADENOCARCINOMA 0/60 0/45 3/75 6/60 COMBINED 0/60 2/45 10/75 9/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/60 0/45 7/75 10/60 OR ADENOCARCINOMA 0/60 0/45 3/75 15/60 COMBINED 0/60 0/45 10/75 23/75 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 7/74 3/60 OR CARCINOMA 0/60 0/45 1/74 1/60 COMBINED 0/60 0/45 7/74 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/60 0/45 29/75 26/60 OR CARCINOMA 0/60 0/45 12/75 12/60 COMBINED 0/60 0/45 35/75 33/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 1/45 3/74 3/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 0/74 1/60 COMBINED 1/60 1/45 3/74 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/60 0/45 7/75 6/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/60 0/45 1/75 0/60 COMBINED 1/60 0/45 8/75 6/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/60 1/45 3/75 6/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 0/60 0/45 3/75 4/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 3/45 7/75 9/60 OR SQUAMOUS CELL CARCINOMA 0/60 1/45 2/75 4/60 COMBINED 0/60 3/45 9/75 13/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/60 0/45 3/75 2/60 OR SQUAMOUS CELL CARCINOMA 0/60 0/45 1/75 3/60 COMBINED 0/60 0/45 4/75 5/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 2/60 4/45 4/75 8/60 OR CARCINOMA 0/60 0/45 2/75 1/60 COMBINED 2/60 4/45 6/75 9/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 3/45 5/75 5/60 OR BASAL CELL CARCINOMA 0/60 0/45 5/75 4/60 COMBINED 0/60 3/45 10/75 9/60; SQUAMOUS CELL PAPILLOMA 0/60 1/45 6/75 5/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 4/75 7/60 COMBINED 0/60 3/45 9/75 12/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/60 10/45 52/75 29/60 OR BASAL CELL CARCINOMA 0/60 1/45 4/75 2/60 COMBINED 0/60 11/45 54/75 30/60; SEBACEOUS GLAND ADENOMA 0/60 0/45 7/75 5/60; KERATOACANTHOMA 1/60 1/45 8/75 5/60; SQUAMOUS CELL PAPILLOMA 0/60 0/45 8/75 15/60 OR SQUAMOUS CELL CARCINOMA 0/60 2/45 10/75 13/60 COMBINED 0/60 2/45 17/75 27/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/60 4/45 11/75 12/60 OR CARCINOMA 0/60 2/45 22/75 35/60 COMBINED 0/57 6/45 32/75 42/60 | Neoplastic Lesions |
| No | TR-390 | 612-82-8 | 3,3'-Dimethylbenzidine dihydrochloride | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 1/60 1/45 13/75 16/60 OR CARCINOMA 0/60 2/45 21/75 23/60 COMBINED 1/60 3/45 32/75 36/60 | Neoplastic Lesions |
| Yes | TR-127 | 99-59-2 | 5-Nitro-o-anisidine | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (ADENOMA, CARCINOMA) | Neoplastic Lesions |
| No | TR-127 | 99-59-2 | 5-Nitro-o-anisidine | Mice | B6C3F1 | Male | Dosed-Feed | Liver | Equivocal Evidence | Equivocal | (CARCINOMA) | Neoplastic Lesions |
| No | TR-127 | 99-59-2 | 5-Nitro-o-anisidine | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-127 | 99-59-2 | 5-Nitro-o-anisidine | Rats | F344/N | Male | Dosed-Feed | Skin | Positive | Positive | (TRICHOEPITHELIOMA, SEBACEOUS ADENOMA, BASAL CELL CARCINOMA, SQUAMOUS CELL CARCINOMA, ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-127 | 99-59-2 | 5-Nitro-o-anisidine | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-127 | 99-59-2 | 5-Nitro-o-anisidine | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | Negative | Not applicable | Not applicable | |
| Yes | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Mice | B6C3F1 | Female | Dosed-Feed | Liver | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Male | Dosed-Feed | Lung | Positive | Positive | (ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Mammary Gland | Positive | Positive | (ADENOCARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Mice | B6C3F1 | Female | Dosed-Feed | Ovary | Positive | Positive | (TUBULAR CELL ADENOMA OR GRANULOSA CELL TUMOR OR LUTEOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Female | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| No | TR-118 | 602-87-9 | 5-Nitroacenaphthene | Rats | F344/N | Male | Dosed-Feed | Zymbal Gland | Positive | Positive | (CARCINOMA) | Neoplastic Lesions |
| Yes | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 1/4 6/48 12/47 3/48 8/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis | Clear Evidence | Clear Evidence | malignant mesothelioma 2/48 2/48 1/48 5/48 8/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis or Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 2/48 2/48 1/48 5/48 8/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 4/46 0/46 2/48 5/45 8/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/46 2/45 2/46 6/47 6/44 squamous cell carcinoma 0/46 0/45 0/46 1/47 2/44 squamous cell papilloma or carcinoma 0/46 2/45 2/46 7/47 8/44 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 0/45 8/44 20/48 32/47 31/43 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/46 13/46 27/47 36/47 39/47 adenocarcinoma 0/46 0/46 0/47 1/47 1/47 adenoma or adenocarcinoma 2/46 13/46 27/47 37/47 39/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 2/48 1/48 0/48 2/48 4/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant Schwannoma 1/48 2/48 3/48 4/48 6/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | adenoma 0/48 0/48 1/48 1/48 3/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 1/47 4/47 6/48 11/45 19/45 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 5/47 6/46 13/47 10/45 19/48 alveolar/bronchiolar adenoma or carcinoma 6/47 6/46 14/47 10/45 20/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/47 1/46 1/48 2/45 4/42 adenocarcinoma 0/47 4/46 6/48 2/45 13/42 adenoacanthoma or adenocarcinoma 0/47 4/46 7/48 4/45 17/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 18/48 24/46 22/47 31/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | squamous cell papilloma or carcinoma 0/48 2/48 1/48 3/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Clear Evidence | benign granulose cell tumor 0/46 1/45 0/48 1/45 5/42 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Pancreas Islet Cell | Clear Evidence | Clear Evidence | adenoma 1/46 2/48 4/48 1/48 6/48 carcinoma 0/46 0/48 0/48 1/48 0/48 adenoma or carcinoma 1/46 2/48 4/48 2/48 6/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma, fibrous histocytoma, myxosarcoma, neurofibrosarcoma, or sarcoma 0/48 0/46 3/48 10/45 6/43 squamous cell carcinoma 0/48 0/46 0/48 0/45 2/43 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | subcutaneous tissue fibroma, fibrosarcoma or sarcoma 1/48 0/48 0/48 1/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 1/48 2/48 1/48 1/48 5/48 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Female | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/48 0/48 1/48 0/48 2/47 carcinoma 0/48 0/48 1/48 3/48 2/47 adenoma or carcinoma 0/48 0/48 2/48 3/48 4/47 | Neoplastic Lesions |
| No | TR-575 | 79-06-1 | Acrylamide | Rats | F344 (NCTR) | Male | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/47 1/48 1/47 1/48 3/48 carcinoma 1/47 2/48 3/47 6/48 6/48 l adenoma or carcinoma 1/47 3/48 4/47 6/48 9/48 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Adrenal Gland Medulla | Clear Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 1/50 3/35 5/64 1/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Adrenal Gland Medulla | Clear Evidence | Equivocal Evidence | PHEOCHROMOCYTOMA 16/50 11/35 24/63 19/49 OR MALIGNANT PHEOCHROMOCYTOMA 2/50 0/35 3/63 2/49 COMBINED 17/50 11/35 27/63 21/49 | May Have Been Related |
| Yes | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 7/48 10/32 10/62 10/50, CARCINOMA 4/48 9/32 19/62 15/50, COMBINED 11/48 17/32 28/62 23/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 12/50 13/35 18/65 5/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 3/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 0/35 1/65 2/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 0/35 15/64 6/50, CARCINOMA 0/50 0/35 6/64 3/50, COMBINED 0/50 0/35 19/64 8/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 2/50 1/35 10/65 15/50, CARCINOMA 0/50 1/35 6/65 7/50, COMBINED 2/50 2/35 15/65 20/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Lung | Clear Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 2/35 1/65 3/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 2/50 2/35 2/65 3/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 2/35 8/65 4/50, ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 1/50 2/35 9/65 4/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Mammary Gland | Clear Evidence | Equivocal Evidence | ADENOCARCINOMA 0/50 3/35 6/65 3/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Equivocal Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/35 1/65 2/50 | May Have Been Related |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 3/35 6/65 4/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 3/65 2/50, COMBINED 0/50 3/35 9/65 6/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 0/50 3/35 5/65 3/50, BASAL CELL CARCINOMA 0/50 1/35 2/65 2/50, COMBINED 0/50 4/35 7/65 5/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 1/50 4/35 26/65 30/50, BASAL CELL CARCINOMA 0/50 1/35 5/65 6/50, COMBINED 1/50 5/35 28/65 32/50; KERATOACANTHOMA 1/50 1/35 4/65 7/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 5/65 5/50, SEBACEOUS GLAND CARCINOMA 1/50 0/35 0/65 1/50, COMBINED 1/50 1/35 5/65 6/50; SQUAMOUS CELL PAPILLOMA 1/50 0/35 3/65 2/50, SQUAMOUS CELL CARCINOMA 0/50 2/35 8/65 7/50, COMBINED 1/50 2/35 11/65 9/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 2/65 6/50, CARCINOMA 0/50 3/35 17/65 13/50, COMBINED 0/50 3/35 18/65 19/50 | Neoplastic Lesions |
| No | TR-405 | 6459-94-5 | C.I. Acid Red 114 | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, CARCINOMA 0/50 0/35 7/65 6/50, COMBINED 0/50 0/35 8/65 7/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Brain | Clear Evidence | Equivocal Evidence | ASTROCYTOMA 0/50 1/35 1/65 2/50 | May Have Been Related |
| Yes | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 5/50 5/31 12/64 12/50, CARCINOMA 2/50 6/31 12/64 15/50, COMBINED 7/50 11/31 24/64 27/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Hematopoietic System | Clear Evidence | Equivocal Evidence | MONONUCLEAR CELL LEUKEMIA 17/50 19/35 28/65 20/50 | May Have Been Related |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Hematopoietic System | Clear Evidence | Clear Evidence | MONONUCLEAR CELL LEUKEMIA 7/50 13/35 27/65 15/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/35 3/65 1/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Large) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 6/65 8/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | ADENOCARCINOMA 0/50 0/35 1/65 3/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Intestines (Small) | Clear Evidence | Clear Evidence | NEOPLASMS 0/50 1/35 0/65 2/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 0/35 2/65 4/50, CARCINOMA 0/50 0/35 0/65 1/50, COMBINED 0/50 0/35 2/65 5/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Liver | Clear Evidence | Clear Evidence | NEOPLASTIC NODULE 0/50 6/35 8/65 7/50, CARCINOMA 0/50 0/35 1/65 4/50, COMBINED 0/50 6/35 9/65 11/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 2/50 3/35 12/65 9/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 8/65 6/50, COMBINED 2/50 4/35 19/65 15/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 9/35 18/65 15/50, SQUAMOUS CELL CARCINOMA 1/50 1/35 6/65 2/50, COMBINED 1/50 10/35 24/65 17/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 6/49 2/35 12/64 8/48, CARCINOMA 2/49 3/35 11/64 1/48, COMBINED 8/49 5/35 23/64 9/48 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/35 5/65 5/50, SQUAMOUS CELL CARCINOMA 0/50 0/35 1/65 0/50, COMBINED 0/50 2/35 6/65 5/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | BASAL CELL ADENOMA 2/50 8/35 23/65 26/50, BASAL CELL CARCINOMA 0/50 2/35 4/65 10/50, COMBINED 2/50 9/35 27/65 28/50; SEBACEOUS GLAND ADENOMA 0/50 1/35 7/65 3/50; SQUAMOUS CELL PAPILLOMA 2/50 3/35 5/65 8/50, SQUAMOUS CELL CARCINOMA 0/50 1/35 7/65 13/50, COMBINED 2/50 4/35 11/65 19/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Uterus/Cervix | Clear Evidence | Clear Evidence | ADENOMA 0/50 0/35 1/65 1/50, ADENOCARCINOMA 1/50 0/35 0/65 3/50, COMBINED 1/50 0/35 1/65 4/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Female | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/35 5/65 3/50, CARCINOMA 0/50 4/35 7/65 14/50, COMBINED 0/50 4/35 11/65 17/50 | Neoplastic Lesions |
| No | TR-397 | 2429-74-5 | C.I. Direct Blue 15 | Rats | F344/N | Male | Dosed-Water | Zymbal Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/35 2/65 4/50, CARCINOMA 1/50 3/35 8/65 17/50, COMBINED 1/50 5/35 10/65 20/50 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | All Organs | Clear Evidence | Equivocal Evidence | Mononuclear Cell Leukemia 21/48 26/48 27/48 27/47 31/48 | May Have Been Related |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | All Organs | Clear Evidence | Clear Evidence | Mononuclear Cell Leukemia 14/48 11/48 21/48 19/48 27/48 | Neoplastic Lesions |
| Yes | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Clitoral Gland | Clear Evidence | Clear Evidence | carcinoma 4/48 6/48 7/48 11/48 14/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/45 3/48 10/47 17/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Epididymis or Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/48 3/48 10/47 17/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 1/45 1/45 1/47 5/45 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 2/45 3/48 2/45 10/41 squamous cell carcinoma 0/47 0/45 0/48 0/45 2/41 squamous cell papilloma or carcinoma 0/47 2/45 3/48 2/45 12/41 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Forestomach | Clear Evidence | Clear Evidence | squamous cell papilloma 0/48 1/48 0/48 0/47 3/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 2/45 19/47 20/47 24/46 40/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Harderian Gland | Clear Evidence | Clear Evidence | adenoma 3/47 17/47 23/47 32/46 42/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Heart | Clear Evidence | Clear Evidence | malignant schwannoma 2/48 3/48 3/48 7/47 8/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 3/46 5/48 3/47 7/47 9/44 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Lung | Clear Evidence | Clear Evidence | alveolar/bronchiolar adenoma 0/47 7/46 7/47 13/47 17/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | adenoacanthoma 0/45 0/48 0/47 1/47 8/45 adenocarcinoma 1/45 1/48 2/47 9/47 11/45 adenoacanthoma or adenocarcinoma 1/45 1/48 2/47 9/47 18/45 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Mammary Gland | Clear Evidence | Clear Evidence | fibroadenoma 16/48 26/48 35/48 33/48 36/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/48 0/48 squamous cell carcinoma 0/48 0/48 0/48 0/48 1/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 2/48 0/48 4/48 squamous cell carcinoma 0/48 0/48 0/48 1/48 2/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 1/48 2/48 2/48 2/48 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa or tongue: squamous cell papilloma or carcinoma 2/48 2/48 2/48 3/47 7/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Oral mucosa: squamous cell papilloma 1/48 1/48 0/48 2/47 3/48 squamous cell carcinoma 1/48 0/48 1/48 1/47 0/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Oral Cavity | Clear Evidence | Clear Evidence | Tongue: squamous cell papilloma 0/48 1/48 0/48 1/47 4/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Ovary | Clear Evidence | Equivocal Evidence | granulosa cell tumor – benign or malignant 0/45 0/47 0/47 3/46 3/44 | May Have Been Related |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Female | Dosed-Water | Skin | Clear Evidence | Clear Evidence | fibrosarcoma 0/45 1/48 2/47 2/47 9/45 sarcoma 0/45 0/48 1/47 3/47 3/45 fibrosarcoma or sarcoma 0/45 1/48 3/47 5/47 12/45 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Mice | MV | Male | Dosed-Water | Skin | Clear Evidence | Clear Evidence | squamous cell papilloma 0/47 1/48 2/47 1/47 8/46 squamous cell carcinoma 0/47 0/48 0/47 0/47 2/46 squamous cell papilloma or carcinoma 0/47 1/48 2/47 1/47 9/46 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Testis | Clear Evidence | Clear Evidence | malignant mesothelioma 0/48 1/47 3/48 6/47 13/48 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Female | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 0/48 3/48 3/46 1/46 5/47 follicular cell carcinoma 0/48 0/48 2/46 3/46 3/47 follicular cell adenoma or carcinoma 0/48 3/48 5/46 4/46 8/47 | Neoplastic Lesions |
| No | TR-588 | 5694-00-8 | Glycidamide | Rats | F344 (NCTR) | Male | Dosed-Water | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | adenoma 2/47 1/42 3/48 3/47 8/46 follicular cell carcinoma 0/47 2/42 3/48 1/47 5/46 follicular cell adenoma or carcinoma 2/47 3/42 6/48 4/47 13/46 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 4/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Brain | Clear Evidence | Clear Evidence | GLIOMA 0/50 5/50 6/50 | Neoplastic Lesions |
| Yes | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Epididymis | Clear Evidence | Equivocal Evidence | SARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Forestomach | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Glandular Stomach | Clear Evidence | Equivocal Evidence | FIBROSARCOMA 0/50 0/50 2/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Harderian Gland | Clear Evidence | Clear Evidence | ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Hematopoietic System | Clear Evidence | Clear Evidence | LEUKEMIA 13/50 14/50 20/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Kidney Tubular Cell | Clear Evidence | Clear Evidence | ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Liver | Clear Evidence | Clear Evidence | ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Lung | Clear Evidence | Clear Evidence | ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mammary Gland | Clear Evidence | Clear Evidence | FIBROADENOMA 3/50 8/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Mesothelium (Abdominal Cavity/Tunica Vaginalis) | Clear Evidence | Clear Evidence | MESOTHELIOMA 3/50 34/50 39/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Oral Cavity | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Skin | Clear Evidence | Clear Evidence | SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Subcutaneous Tissue | Clear Evidence | Clear Evidence | SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Female | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Thyroid Gland Follicular Cell | Clear Evidence | Clear Evidence | ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Male | Gavage | Urinary Bladder | Clear Evidence | Equivocal Evidence | CARCINOMA 0/50 1/50 1/50 | May Have Been Related |
| No | TR-374 | 556-52-5 | Glycidol | Mice | B6C3F1 | Female | Gavage | Uterus/Cervix | Clear Evidence | Clear Evidence | CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50 | Neoplastic Lesions |
| No | TR-374 | 556-52-5 | Glycidol | Rats | F344/N | Male | Gavage | Zymbal Gland | Clear Evidence | Clear Evidence | CARCINOMA 1/50 3/50 6/50 | Neoplastic Lesions |
| No | TR-368 | 389-08-2 | Nalidixic acid | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | No Evidence | Not applicable | Not applicable | |
| Yes | TR-368 | 389-08-2 | Nalidixic acid | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Clear Evidence | Clear Evidence | ADENOMA 4/46 10/46 11/47, PAPILLOMA 0/46 1/46 0/47, OR CARCINOMA 1/46 4/46 5/47 COMBINED 5/46 15/46 16/47 | Neoplastic Lesions |
| No | TR-368 | 389-08-2 | Nalidixic acid | Rats | F344/N | Male | Dosed-Feed | Preputial Gland | Clear Evidence | Clear Evidence | ADENOMA 2/49 10/49 10/47, PAPILLOMA 1/49 0/49 0/47, OR CARCINOMA 0/49 10/49 12/47 COMBINED 3/49 19/49 20/47 | Neoplastic Lesions |
| No | TR-368 | 389-08-2 | Nalidixic acid | Mice | B6C3F1 | Male | Dosed-Feed | Subcutaneous Tissue | Equivocal Evidence | Equivocal Evidence | FIBROMA 1/50 3/50 3/50 OR FIBROSARCOMA 4/50 6/50 11/50 COMBINED 5/50 9/50 14/50 | Neoplastic Lesions |
| No | TR-442 | 62-23-7 | p-Nitrobenzoic acid | Mice | B6C3F1 | Female | Dosed-Feed | Unspecified | No Evidence | Not applicable | Not applicable | |
| No | TR-442 | 62-23-7 | p-Nitrobenzoic acid | Mice | B6C3F1 | Male | Dosed-Feed | Unspecified | No Evidence | Not applicable | Not applicable | |
| Yes | TR-442 | 62-23-7 | p-Nitrobenzoic acid | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Some Evidence | Some Evidence | ADENOMA 4/50 12/49 10/49 12/50 OR CARCINOMA 1/50 2/49 5/49 4/50 COMBINED 4/50 14/49 15/49 15/50 | Neoplastic Lesions |
| Yes | TR-498 | 99-99-0 | p-Nitrotoluene | Rats | F344/N | Female | Dosed-Feed | Clitoral Gland | Some Evidence | Some Evidence | ADENOMA OR CARCINOMA 8/50 12/50 20/50 8/49 | Neoplastic Lesions |
| No | TR-498 | 99-99-0 | p-Nitrotoluene | Mice | B6C3F1 | Male | Dosed-Feed | Lung | Equivocal Evidence | Equivocal Evidence | ALVEOLAR/BRONCHIOLAR ADEMONA OR CARCINOMA 8/50 14/50 12/50 19/50 | Neoplastic Lesions |
| No | TR-498 | 99-99-0 | p-Nitrotoluene | Rats | F344/N | Male | Dosed-Feed | Skin | Equivocal Evidence | Equivocal Evidence | (SUBCUTANEOUS): FIBROMA 1/50 2/50 7/50 1/50 FIBROMA OR FIBROSARCOMA 1/50 2/50 9/50 1/50 | Neoplastic Lesions |